Crinetics Pharmaceuticals, Inc. Income Statement
CRNX / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Crinetics Pharmaceuticals, Inc. reported $8M in revenue and $465M in net loss for FY2025. Revenue has grown at a 33.1% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $1.0M | $4.0M | $4.7M | $1.1M | $2.4M | $2.0M | $589.0K | $2.0M | $589.0K |
| Cost of Revenue | $1.1M | $0 | $0 | - | - | - | - | - | - | - |
| SG&A Expense | $191.3M | $99.7M | $58.1M | $42.4M | $24.5M | $6.7M | $1.9M | $1.5M | $1.9M | $1.5M |
| R&D Expense | $332.1M | $240.2M | $168.5M | $130.2M | $84.3M | $24.5M | $9.2M | $5.1M | $9.2M | $5.1M |
| Operating Income | -$516.8M | -$338.9M | -$222.6M | -$167.9M | -$107.7M | -$28.7M | -$9.1M | -$6.0M | -$9.1M | -$6.0M |
| Interest Expense | - | - | - | - | - | - | - | $11.0K | $8.0K | $11.0K |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$465.3M | -$298.4M | -$214.5M | -$163.9M | -$107.6M | -$27.1M | -$9.2M | -$6.0M | -$9.2M | -$6.0M |
| EPS (Basic) | -$4.95 | -$3.69 | -$3.69 | -$3.15 | -$2.80 | - | - | - | - | - |
| EPS (Diluted) | -$4.95 | -$3.69 | -$3.69 | -$3.15 | -$2.80 | -$2.23 | -$6.68 | -$5.96 | - | -$5.96 |
| Shares Outstanding | 95.6M | 92.9M | 58.1M | 53.9M | 47.6M | 24.3M | 24.1K | 1.5M | 1.4M | 1.0M |
| Operating Margin | -6714.8% | -32613.5% | - | -3544.1% | -9990.9% | -1182.5% | -446.3% | -1026.2% | - | -1026.2% |
| Profit Margin | -6046.2% | -28720.7% | - | -3460.4% | -9985.3% | -1116.8% | -447.8% | -1021.9% | - | -1021.9% |